Can medications cause brain lesions?

Can Medications Cause Brain Lesions?

Yes, medications can definitively cause brain lesions, particularly anticancer therapies, immunosuppressive agents, and certain immunotherapies, with MRI-detectable abnormalities ranging from reversible white matter changes to permanent structural damage.

Anticancer Therapy-Induced Brain Lesions

The most well-documented medication-induced brain lesions occur with systemic anticancer therapies 1. These medications cause several distinct patterns of brain injury:

Posterior Reversible Encephalopathy Syndrome (PRES)

• MRI findings: Bilateral parietal-occipital lobe hyperintensities on T2-weighted imaging, predominantly affecting white matter more than grey matter
• Causative agents: High-dose chemotherapy, immunosuppressive drugs (especially ciclosporin), agents used in stem-cell or solid organ transplantation
• Risk factors: Pre-existing hypertension, renal impairment, autoimmune diseases
• Reversibility: Usually reversible within 2 weeks with cessation of therapy and blood pressure control 1
• Critical action: Very stringent blood pressure control is crucial; discontinue the offending agent immediately

Acute Cerebellar Syndrome

• MRI findings: T2-weighted hyperintensities in the cerebellum
• Causative agents: High-dose cytarabine (most common), bortezomib, rituximab, trastuzumab (rare)
• Timing: Manifests 2-5 days after treatment initiation
• Risk factors: Liver/renal impairment, very high drug doses, age >40 years
• Reversibility: Uncertain—ranges from complete remission to persistent disabling ataxia 1

Spinal Cord Lesions (Myelopathy)

• MRI findings: T2-weighted lesions in the dorsal column of the spinal cord
• Causative agents: Intrathecal methotrexate, cytarabine, cisplatin, carmustine, thiotepa
• Mechanism: High drug levels in CSF for ≥24 hours
• Risk factors: Concurrent craniospinal radiotherapy, frequent lumbar injections
• Treatment: Consider intrathecal steroids or high-dose folate metabolites for methotrexate-induced cases 1

Progressive Multifocal Leukoencephalopathy (PML)

• MRI findings: Typical demyelinating lesions
• Causative agents: Immunomodulatory drugs and antibodies in patients with hematological malignancies
• Mechanism: JC virus reactivation due to immunosuppression (CD4/CD8 depletion)
• Prevalence: 0.07% in patients with hematological malignancies
• Prognosis: Devastating and often irreversible; no specific treatment available 1

Immunotherapy-Related Brain Lesions

CAR T-cell therapies and immune checkpoint inhibitors can cause immune-mediated neurotoxicity with MRI abnormalities 2:

• Presentation: Immune effector cell-associated neurotoxicity syndrome (ICANS)
• Imaging requirement: MRI brain with and without contrast for grade ≥2 neurotoxicity
• Management: High-dose corticosteroids (dexamethasone 10 mg IV) with repeat neuroimaging every 2-3 days for persistent grade ≥3 toxicity

Other Medication Classes

Antipsychotics

Research suggests antipsychotics cause regional rather than global brain volume changes 3:

• Typical antipsychotics specifically increase basal ganglia volume
• Differential effects on thalamus and cortex between typical and atypical agents
• These are structural changes, not acute lesions, but represent medication-induced brain alterations

Antiepileptic Drugs

Certain antiepileptic drugs can cause brain damage, particularly in immature brains 4:

• Phenobarbital and clonazepam cause neuronal necrosis and apoptosis in developing brains
• Phenobarbital effects are more severe and persistent than clonazepam
• These effects occur even at therapeutic plasma concentrations

Clinical Algorithm for Suspected Medication-Induced Brain Lesions

When evaluating a patient with new brain lesions on MRI:

1. Obtain complete medication history, specifically:

   • All anticancer therapies (current and recent)
   • Immunosuppressive agents
   • Immunotherapies (CAR T-cells, checkpoint inhibitors)
   • Intrathecal medications
   • Duration and dosing of all agents

2. Assess risk factors:

   • Hypertension (especially poorly controlled)
   • Renal impairment
   • Autoimmune diseases
   • Recent stem-cell or organ transplantation
   • Age >40 years for cerebellar toxicity

3. Match MRI pattern to medication syndrome:

   • Bilateral parietal-occipital white matter → PRES
   • Cerebellar hyperintensities → Acute cerebellar syndrome
   • Spinal cord dorsal column → Myelopathy
   • Demyelinating lesions + immunosuppression → PML

4. Immediate management:

   • Discontinue the offending agent (most critical step)
   • Control blood pressure aggressively for PRES
   • Initiate corticosteroids for immunotherapy-related toxicity
   • Consider intrathecal steroids for myelopathy

Critical Pitfalls to Avoid

• Do not assume all brain lesions are disease progression in cancer patients—always consider drug toxicity 5
• Do not restart the same agent without careful risk-benefit analysis, as recurrence is likely
• Do not delay imaging when neurotoxicity is suspected—early detection improves reversibility
• Do not overlook medication history when interpreting brain MRI; absence of this information leads to misdiagnosis 5

The evidence unequivocally demonstrates that medications—particularly anticancer therapies and immunosuppressive agents—can cause distinct, recognizable brain lesions with significant morbidity and potential mortality if not promptly recognized and managed.